<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2024.1341423</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Sex differences in functional outcomes of intravenous thrombolysis among patients with lacunar stroke</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wueger</surname>
<given-names>Patrizia</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2601838/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Noseda</surname>
<given-names>Roberta</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/851532/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pagnamenta</surname>
<given-names>Alberto</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1952398/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bianco</surname>
<given-names>Giovanni</given-names>
</name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1007651/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Seiffge</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/406115/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Michel</surname>
<given-names>Patrik</given-names>
</name>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nedeltchev</surname>
<given-names>Krassen</given-names>
</name>
<xref ref-type="aff" rid="aff9"><sup>9</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/276682/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bonati</surname>
<given-names>Leo</given-names>
</name>
<xref ref-type="aff" rid="aff10"><sup>10</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>K&#x00E4;gi</surname>
<given-names>Georg</given-names>
</name>
<xref ref-type="aff" rid="aff11"><sup>11</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/195219/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niederhauser</surname>
<given-names>Julien</given-names>
</name>
<xref ref-type="aff" rid="aff12"><sup>12</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nyffeler</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="aff13"><sup>13</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/126991/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luft</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="aff14"><sup>14</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/74961/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wegener</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="aff14"><sup>14</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/410545/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schelosky</surname>
<given-names>Ludwig</given-names>
</name>
<xref ref-type="aff" rid="aff15"><sup>15</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Medlin</surname>
<given-names>Friedrich</given-names>
</name>
<xref ref-type="aff" rid="aff16"><sup>16</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1137208/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodic</surname>
<given-names>Biljana</given-names>
</name>
<xref ref-type="aff" rid="aff17"><sup>17</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peters</surname>
<given-names>Nils</given-names>
</name>
<xref ref-type="aff" rid="aff18"><sup>18</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Renaud</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="aff19"><sup>19</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mono</surname>
<given-names>Marie Luise</given-names>
</name>
<xref ref-type="aff" rid="aff20"><sup>20</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/937340/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carrera</surname>
<given-names>Emmanuel</given-names>
</name>
<xref ref-type="aff" rid="aff21"><sup>21</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/168886/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fischer</surname>
<given-names>Urs</given-names>
</name>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff10"><sup>10</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Marchis</surname>
<given-names>Gian Marco</given-names>
</name>
<xref ref-type="aff" rid="aff11"><sup>11</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cereda</surname>
<given-names>Carlo W.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/433769/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Faculty of Biomedical Sciences, Universit&#x00E0; Della Svizzera Italiana</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country></aff>
<aff id="aff2"><sup>2</sup><institution>Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country></aff>
<aff id="aff3"><sup>3</sup><institution>Clinical Trial Unit, Ente Ospedaliero Cantonale</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Intensive Care, Ente Ospedaliero Cantonale</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country></aff>
<aff id="aff5"><sup>5</sup><institution>Division of Pneumology, University of Geneva</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country></aff>
<aff id="aff6"><sup>6</sup><institution>Neurocentre of Southern Switzerland, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country></aff>
<aff id="aff7"><sup>7</sup><institution>Department of Neurology, University Hospital Bern</institution>, <addr-line>Bern</addr-line>, <country>Switzerland</country></aff>
<aff id="aff8"><sup>8</sup><institution>Stroke Center, Neurology Service, Lausanne University Hospital</institution>, <addr-line>Lausanne</addr-line>, <country>Switzerland</country></aff>
<aff id="aff9"><sup>9</sup><institution>Department of Neurology, Kantonsspital Aarau</institution>, <addr-line>Aarau</addr-line>, <country>Switzerland</country></aff>
<aff id="aff10"><sup>10</sup><institution>Department of Neurology and Stroke Center, University Hospital Basel and University of Basel</institution>, <addr-line>Basel</addr-line>, <country>Switzerland</country></aff>
<aff id="aff11"><sup>11</sup><institution>Department of Neurology, Kantonsspital St. Gallen</institution>, <addr-line>St. Gallen</addr-line>, <country>Switzerland</country></aff>
<aff id="aff12"><sup>12</sup><institution>Stroke Unit, Hopital Nyon</institution>, <addr-line>Nyon</addr-line>, <country>Switzerland</country></aff>
<aff id="aff13"><sup>13</sup><institution>Center of Neurology and Neurorehabilitation, Luzerner Kantonsspital</institution>, <addr-line>Luzern</addr-line>, <country>Switzerland</country></aff>
<aff id="aff14"><sup>14</sup><institution>Department of Neurology, Universit&#x00E4;tsspital Z&#x00FC;rich</institution>, <addr-line>Z&#x00FC;rich</addr-line>, <country>Switzerland</country></aff>
<aff id="aff15"><sup>15</sup><institution>Division of Neurology, Kantonsspital M&#x00FC;nsterlingen</institution>, <addr-line>M&#x00FC;nsterlingen</addr-line>, <country>Switzerland</country></aff>
<aff id="aff16"><sup>16</sup><institution>Division of Neurology, HFR Fribourg, Stroke Unit</institution>, <addr-line>Fribourg</addr-line>, <country>Switzerland</country></aff>
<aff id="aff17"><sup>17</sup><institution>Department of Neurology, Kantonsspital Winterthur</institution>, <addr-line>Winterthur</addr-line>, <country>Switzerland</country></aff>
<aff id="aff18"><sup>18</sup><institution>Department of Neurology and Stroke Center, Hirslanden Hospital</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country></aff>
<aff id="aff19"><sup>19</sup><institution>Division of Neurology, Pourtal&#x00E8;s Hospital</institution>, <addr-line>Neuchatel</addr-line>, <country>Switzerland</country></aff>
<aff id="aff20"><sup>20</sup><institution>Stroke Unit, Stadtspital Waid und Triemli</institution>, <addr-line>Z&#x00FC;rich</addr-line>, <country>Switzerland</country></aff>
<aff id="aff21"><sup>21</sup><institution>Department of Neurology, H&#x00F4;pitaux Universitaires de Gen&#x00E8;ve</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country></aff>
<author-notes>
<fn id="fn0002" fn-type="edited-by"><p>Edited by: Francesco Corea, Azienda USL Umbria 2, Italy</p></fn>
<fn id="fn0003" fn-type="edited-by"><p>Reviewed by: Marialuisa Zedde, IRCCS Local Health Authority of Reggio Emilia, Italy</p>
<p>Massimo Del Sette, Ente Ospedaliero Ospedali Galliera, Italy</p>
<p>Ana Isabel Fumagalli, Sanatorio Parque Rosario Argentina, Argentina</p></fn>
<corresp id="c001">&#x002A;Correspondence: Carlo W. Cereda, <email>carlo.cereda@eoc.ch</email></corresp>
<fn id="fn0001" fn-type="equal"><p><sup>&#x2020;</sup>These authors share first authorship</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1341423</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>11</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Wueger, Noseda, Pagnamenta, Bianco, Seiffge, Michel, Nedeltchev, Bonati, K&#x00E4;gi, Niederhauser, Nyffeler, Luft, Wegener, Schelosky, Medlin, Rodic, Peters, Renaud, Mono, Carrera, Fischer, De Marchis and Cereda.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Wueger, Noseda, Pagnamenta, Bianco, Seiffge, Michel, Nedeltchev, Bonati, K&#x00E4;gi, Niederhauser, Nyffeler, Luft, Wegener, Schelosky, Medlin, Rodic, Peters, Renaud, Mono, Carrera, Fischer, De Marchis and Cereda</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Background</title>
<p>This study aimed to assess if there are sex differences in the functional outcome of intravenous thrombolysis (IVT) among patients with lacunar stroke (LS).</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>Consecutive patients admitted from 1 January 2014 to 31 January 2020 to hospitals participating in the Swiss Stroke Registry presenting with LS and treated with IVT were included. The study population was then divided into two groups based on patient sex, and a multivariable ordinal logistic regression analysis was performed to uncover sex differences in the modified Rankin Scale (mRS) score at 90&#x2009;days after stroke.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>A total of 413 patients with LS were treated with IVT: 177 (42.9%) women and 236 (57.1%) men. Women were older than men (median age 74&#x2009;years, 25th&#x2013;75th percentiles 67&#x2013;84&#x2009;years versus 70&#x2009;years, 25th&#x2013;75th percentiles 60&#x2013;80&#x2009;years, value of p 0.001) and, after adjustment for meaningful variables, showed more frequently increased odds of a higher mRS score at 90&#x2009;days after stroke (adjusted odds ratio 1.49, 95% confidence interval 1.01&#x2013;2.19, value of p 0.044).</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>This study showed that female sex increased the odds of a worse functional response to IVT in patients with LS. Future studies should further elucidate the mechanisms underlying such sex differences.</p>
</sec>
</abstract>
<kwd-group>
<kwd>lacunar stroke</kwd>
<kwd>intravenous thrombolysis</kwd>
<kwd>sex differences</kwd>
<kwd>functional outcome</kwd>
<kwd>cohort study</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="18"/>
<page-count count="6"/>
<word-count count="3436"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Stroke</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<label>1</label>
<title>Introduction</title>
<p>Lacunar stroke (LS), which accounts for about a quarter of all acute ischaemic strokes (AIS) (<xref ref-type="bibr" rid="ref1">1</xref>), is a sequela of cerebral small vessel disease (cSVD), a disorder of cerebral microvessels whose underlying pathogenesis remains not completely understood (<xref ref-type="bibr" rid="ref2">2</xref>&#x2013;<xref ref-type="bibr" rid="ref4">4</xref>). Consequently, there are extensive debates on whether LS would benefit from acute reperfusion with intravenous thrombolysis (IVT) (<xref ref-type="bibr" rid="ref5">5</xref>, <xref ref-type="bibr" rid="ref6">6</xref>), which is nowadays the approved treatment for AIS regardless of stroke subtype (<xref ref-type="bibr" rid="ref7">7</xref>). It was shown that a better functional outcome was present in patients with LS treated with IVT as compared to patients with LS not treated with IVT (<xref ref-type="bibr" rid="ref8">8</xref>) and that the functional outcome after IVT did not differ in patients with LS compared with other stroke subtypes (<xref ref-type="bibr" rid="ref9">9</xref>).</p>
<p>LS prevalence is higher with age (<xref ref-type="bibr" rid="ref10">10</xref>) and seems to be more frequent and severe in men than women (<xref ref-type="bibr" rid="ref11">11</xref>, <xref ref-type="bibr" rid="ref12">12</xref>). Nevertheless, it has not yet been clarified whether there are sex differences in functional outcomes following IVT, specifically in patients with LS. Therefore, this study aimed to assess sex differences in the functional outcome of IVT as a distribution of the modified Rankin Scale (mRS) score at 90&#x2009;days after stroke among patients with LS from the Swiss Stroke Registry (SSR).</p>
</sec>
<sec sec-type="methods" id="sec6">
<label>2</label>
<title>Methods</title>
<sec id="sec7">
<label>2.1</label>
<title>Swiss stroke registry</title>
<p>This was a multicenter retrospective cohort study in the SSR, a national registry that collects standardized data from all consecutive patients admitted to certified stroke units and stroke centers across Switzerland. Data collected encompass patient demographics, medical history, medications used before admission, pre-stroke functional status, diagnostic procedures, in-hospital treatments, and outcomes (both during hospitalization and 90&#x2009;days after stroke). The Clinical Trial Unit of the University Hospital of Basel, Switzerland, manages the database and provides irreversible anonymized data for study purposes. At the time of hospitalization, patients were informed about the collection and utilization of their personal data through informed consent. The registry and the present study were both approved by the responsible ethics committee (CE Req-2020-01042).</p>
</sec>
<sec id="sec8">
<label>2.2</label>
<title>Study population</title>
<p>Consecutive patients admitted from 1 January 2014 to 31 January 2020 to hospitals participating in the SSR presenting with LS and treated with IVT were included (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In the SSR, the etiology of AIS refers to the TOAST classification (<xref ref-type="bibr" rid="ref13">13</xref>). The diagnosis of LS was suspected in patients who presented with a recognized lacunar syndrome (e.g., pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, sensorimotor stroke, and dysarthria-clumsy hand syndrome) or other acute stroke symptoms without cortical involvement and was eventually confirmed upon finding a small subcortical infarct on CT or MRI. The study population was divided into two groups based on patient sex and thereafter compared in terms of patient demographics (age at the time of stroke onset and use of antiplatelets and/or anticoagulants before hospital admission), medical history (previous stroke, previous transient ischemic attack, previous intracranial hemorrhage, hypertension, diabetes, hyperlipidemia, smoking, and atrial fibrillation), pre-stroke functional status (i.e., disability as mRS score ranging from 0&#x2009;=&#x2009;no symptoms to 6&#x2009;=&#x2009;death), and stroke severity assessed as National Institutes of Health Stroke Scale (NIHSS) - score at admission (a measure of neurological deficits, ranging from 0 to 42, with higher scores indicating greater stroke severity), in-hospital treatments, and outcomes at 90&#x2009;days after stroke.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption><p>CONSORT diagram showing the selection process of patients included in the study. SSR, Swiss Stroke Registry; IVT, intravenous thrombolysis; MT, mechanical thrombectomy; LVO, large vessel occlusion.</p></caption>
<graphic xlink:href="fneur-15-1341423-g001.tif"/>
</fig>
</sec>
<sec id="sec9">
<label>2.3</label>
<title>Outcomes</title>
<p>The primary outcome was defined as the mRS score at 90&#x2009;days after stroke and assessed in an ordinal logistic regression analysis (shift analysis). The safety outcome was in-hospital symptomatic intracerebral hemorrhage (sICH), defined as ICH with &#x2265;4-point worsening of the NIHSS score occurring within 7&#x2009;days of AIS onset.</p>
</sec>
<sec id="sec10">
<label>2.4</label>
<title>Statistical analyses</title>
<p>Quantitative data were presented as absolute numbers with percentages (if categorical) or as median with the 25th and 75th percentiles (if continuous). Comparisons of the different variables according to patient sex were performed with the Mann&#x2013;Whitney test or chi-squared test, as appropriate. To investigate sex differences in the primary functional outcome of IVT among patients with LS, ordinal logistic regression was used. At first, the association between patient sex and other independent variables of clinical significance and the mRS score at 90&#x2009;days after stroke was assessed in univariate models. Subsequently, patient sex and variables with a value of <italic>p</italic> &#x2264;0.1 from univariate analyses were included in a multivariable ordinal logistic regression model to provide an overall point estimate as an odds ratio representing a shift in scores on the mRS at 90&#x2009;days after stroke. All analyses were performed two-sided, and a value of p less than 0.05 was considered statistically significant. Analyses were performed using Statistical Analysis System Software (version 9.4; SA Institute, Cary, NC).</p>
</sec>
</sec>
<sec sec-type="results" id="sec11">
<label>3</label>
<title>Results</title>
<p>Out of 5,412 AIS patients treated with IVT, 413 suffered from LS. <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref> shows the distribution of hospitals participating in the SSR from which patients included in the present study were selected. There were 177 women (42.9%) and 236 men (57.1%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Women were older than men (median age 74&#x2009;years, 25th&#x2013;75th percentiles 67&#x2013;84&#x2009;years, versus 70&#x2009;years, 25th&#x2013;75th percentiles 60&#x2013;80&#x2009;years, value of <italic>p</italic>&#x2009;=&#x2009;0.001). No sex differences were observed in the use of antiplatelets before admission, medical history, pre-stroke disability, or NIHSS score at admission. Female patients showed more frequently worse functional outcomes (both primary and secondary) than male patients, among whom an event of in-hospital sICH occurred (<xref ref-type="table" rid="tab1">Table 1</xref>). No events of sICH occurred among female patients.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Characteristics of the study population according to patient sex.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Characteristic</th>
<th align="center" valign="top">Females<break/>(<italic>N</italic>&#x2009;=&#x2009;177)</th>
<th align="center" valign="top">Males<break/>(<italic>N</italic>&#x2009;=&#x2009;236)</th>
<th align="center" valign="top">Value of <italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age, years, No. (%)<break/>&#x0003C;65<break/>65&#x2013;74<break/>&#x2265;75<break/>median [25th&#x2013;75th percentiles]</td>
<td align="char" valign="top" char="("><break/>31 (17.5)<break/>58 (32.8)<break/>88 (49.7)<break/>74 [67&#x2013;84]</td>
<td align="char" valign="top" char="("><break/>79 (33.5)<break/>68 (28.8)<break/>89 (37.7)<break/>70 [60&#x2013;80]</td>
<td align="char" valign="top" char="."><break/>0.001<break/>&#x0003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">Antiplatelets before admission, No. (%)<break/>No<break/>Yes, single therapy<break/>Aspirin<break/>Clopidogrel</td>
<td align="char" valign="top" char="("><break/>120 (67.8)<break/>57 (32.2)<break/>49 (27.7)<break/>8 (4.5)</td>
<td align="char" valign="top" char="("><break/>160 (67.8)<break/>76 (32.2)<break/>59 (25.0)<break/>17 (7.2)</td>
<td align="char" valign="top" char="."><break/>1.000<break/>0.539<break/>0.258</td>
</tr>
<tr>
<td align="left" valign="top">Medical history, No.(%)<break/>Previous stroke<break/>Previous transient ischemic attack<break/>Previous intracranial hemorrhage<break/>Hypertension<break/>Diabetes<break/>Hyperlipidemia<break/>Smoking<break/>Atrial fibrillation</td>
<td align="char" valign="top" char="("><break/>16 (9.0)<break/>12 (6.8)<break/>5 (2.8)<break/>145 (81.9)<break/>35 (19.8)<break/>128 (72.3)<break/>32 (18.1)<break/>4 (2.3)</td>
<td align="char" valign="top" char="("><break/>29 (12.3)<break/>11 (4.7)<break/>2 (0.9)<break/>182 (77.1)<break/>59 (25.0)<break/>185 (78.4)<break/>83 (35.2)<break/>5 (2.1)</td>
<td align="char" valign="top" char="."><break/>0.294<break/>0.353<break/>0.144<break/>0.234<break/>0.210<break/>0.154<break/>0.0001<break/>1.000</td>
</tr>
<tr>
<td align="left" valign="top">Prestroke disability, No. (%)<break/>mRS score 0<break/>mRS score 1<break/>mRS score 2<break/>mRS score 3<break/>mRS score 4<break/>mRS score 5</td>
<td align="char" valign="top" char="("><break/>107 (60.5)<break/>26 (14.7)<break/>6 (3.4)<break/>11 (6.2)<break/>1 (0.6)<break/>1 (0.6)</td>
<td align="char" valign="top" char="("><break/>153 (64.8)<break/>23 (9.8)<break/>12 (5.1)<break/>7 (3.0)<break/>4 (1.7)<break/>-</td>
<td align="char" valign="top" char="."><break/>0.164</td>
</tr>
<tr>
<td align="left" valign="top">Onset to treatment time (min)<break/>median [25th&#x2013;75th percentiles]</td>
<td align="char" valign="top" char="(">122 (68.9)<break/>207 [131&#x2013;242]</td>
<td align="char" valign="top" char="(">178 (75.4)<break/>200 [132&#x2013;228]</td>
<td align="char" valign="top" char=".">0.497</td>
</tr>
<tr>
<td align="left" valign="top">Door to treatment time (min)<break/>median [25th&#x2013;75th percentiles]</td>
<td align="char" valign="top" char="(">166 (93.8)<break/>38 [28&#x2013;53]</td>
<td align="char" valign="top" char="(">220 (93.2)<break/>39 [29&#x2013;55]</td>
<td align="char" valign="top" char=".">0.709</td>
</tr>
<tr>
<td align="left" valign="top">NIHSS at admission, No. (%)<break/>0&#x2013;4<break/>5&#x2013;10<break/>11&#x2013;15<break/>16&#x2013;21<break/>&#x2265;22<break/>median [25th&#x2013;75th percentiles]</td>
<td align="char" valign="top" char="("><break/>69 (39.0)<break/>95 (53.7)<break/>12 (6.8)<break/>1 (0.6)<break/>0 (0.0)<break/>5 [3.5&#x2013;7]</td>
<td align="char" valign="top" char="("><break/>108 (45.8)<break/>111 (47.0)<break/>12 (5.1)<break/>4 (1.7)<break/>1 (0.4)<break/>5 [4&#x2013;7]</td>
<td align="char" valign="top" char="."><break/>0.368<break/>0.496</td>
</tr>
<tr>
<td align="left" valign="top">Functional outcomes at 90&#x2009;days after stroke, No. (%)<break/>Primary<break/>mRS score<break/>0<break/>1<break/>2<break/>3<break/>4<break/>5<break/>6<break/>Secondary<break/>Functional independence (mRS 0&#x2013;2)</td>
<td align="char" valign="top" char="("><break/><break/>42 (23.7)<break/>45 (25.4)<break/>33 (18.6)<break/>29 (16.4)<break/>26 (14.7)<break/>0 (0)<break/>2 (1.1)<break/>120 (67.8)</td>
<td align="char" valign="top" char="("><break/><break/><break/>82 (34.8)<break/>61 (25.9)<break/>48 (20.3)<break/>20 (8.5)<break/>18 (7.6)<break/>0 (0)<break/>7 (3.0)<break/>191 (80.9)</td>
<td align="char" valign="top" char="."><break/><break/><break/>0.007<break/>0.002</td>
</tr>
<tr>
<td align="left" valign="top">Safety outcome at 90&#x2009;days after stroke, No. (%)<break/>In-hospital sICH</td>
<td align="char" valign="top" char="("><break/>0 (0)</td>
<td align="char" valign="top" char="("><break/>1 (0.6)</td>
<td align="char" valign="top" char="."><break/>0.430</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IVT, intravenous thrombolysis.</p>
</table-wrap-foot>
</table-wrap>
<p>Univariate ordinal logistic regression analyses demonstrated that patient sex, use of antiplatelets before admission, previous stroke, medical history of hypertension and hyperlipidemia, as well as pre-stroke disability and NIHSS at admission, were associated with the mRS score at 90&#x2009;days after stroke (<xref ref-type="table" rid="tab2">Table 2</xref>). After adjustment, female sex was associated with increased odds of presenting a higher mRS score at 90&#x2009;days after stroke than male sex (adjusted OR 1.49, 95% CI 1.01&#x2013;2.19, value of p 0.044, <xref ref-type="table" rid="tab2">Table 2</xref>).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption><p>Univariate and multivariable logistic regression analyses.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" rowspan="2">Independent variables</th>
<th align="center" valign="middle" colspan="4">Distribution of the mRS score at 90&#x2009;days after stroke<break/>(<italic>shift analysis</italic>)</th>
</tr>
<tr>
<th align="center" valign="middle">Univariate model<break/>OR [95% CI]</th>
<th align="center" valign="middle">Value of <italic>p</italic></th>
<th align="center" valign="middle">Multivariable model<break/>Adjusted OR [95% CI]</th>
<th align="center" valign="middle">Value of <italic>p</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Patient sex (female versus male)</td>
<td align="char" valign="middle" char="[">0.59 [0.42&#x2013;0.84]</td>
<td align="char" valign="top" char="."><bold>0.003</bold></td>
<td align="char" valign="top" char="[">1.49 [1.01&#x2013;2.19]</td>
<td align="char" valign="top" char=".">0.044</td>
</tr>
<tr>
<td align="left" valign="middle">Patient age (&#x2265;65&#x2009;years versus&#x2009;&#x003C;&#x2009;65&#x2009;years)</td>
<td align="char" valign="middle" char="[">0.77 [0.52&#x2013;1.14]</td>
<td align="char" valign="top" char=".">0.197</td>
<td align="char" valign="top" char="[">&#x2013;</td>
<td align="char" valign="top" char=".">&#x2013;</td>
</tr>
<tr>
<td align="left" valign="top">Use of antiplatelets before admission (yes versus no)</td>
<td align="char" valign="top" char="[">0.48 [0.33&#x2013;0.69]</td>
<td align="char" valign="top" char="."><bold>&#x003C;0.0001</bold></td>
<td align="char" valign="top" char="[">1.47 [0.94&#x2013;2.29]</td>
<td align="char" valign="top" char=".">0.094</td>
</tr>
<tr>
<td align="left" valign="top">Previous stroke (yes versus no)</td>
<td align="char" valign="top" char="[">0.50 [0.29&#x2013;0.87]</td>
<td align="char" valign="top" char="."><bold>0.014</bold></td>
<td align="char" valign="top" char="[">1.16 [0.59&#x2013;2.30]</td>
<td align="char" valign="top" char=".">0.663</td>
</tr>
<tr>
<td align="left" valign="top">Previous transient ischemic attack (yes versus no)</td>
<td align="char" valign="top" char="[">1.01 [0.48&#x2013;2.13]</td>
<td align="char" valign="top" char=".">0.9901</td>
<td align="char" valign="top" char="[">&#x2013;</td>
<td align="char" valign="top" char=".">&#x2013;</td>
</tr>
<tr>
<td align="left" valign="top">Hypertension (yes versus no)</td>
<td align="char" valign="top" char="[">0.70 [0.46&#x2013;1.08]</td>
<td align="char" valign="top" char="."><bold>0.108</bold></td>
<td align="char" valign="top" char="[">1.51 [0.91&#x2013;4.50]</td>
<td align="char" valign="top" char=".">0.112</td>
</tr>
<tr>
<td align="left" valign="top">Diabetes (yes versus no)</td>
<td align="char" valign="top" char="[">0.90 [0.60&#x2013;1.36]</td>
<td align="char" valign="top" char=".">0.6126</td>
<td align="char" valign="top" char="[">&#x2013;</td>
<td align="char" valign="top" char=".">&#x2013;</td>
</tr>
<tr>
<td align="left" valign="top">Hyperlipidemia (yes versus no)</td>
<td align="char" valign="top" char="[">1.39 [0.93&#x2013;2.08]</td>
<td align="char" valign="top" char="."><bold>0.105</bold></td>
<td align="char" valign="top" char="[">0.50 [0.32&#x2013;0.80]</td>
<td align="char" valign="top" char=".">0.004</td>
</tr>
<tr>
<td align="left" valign="top">Smoking (yes versus no)</td>
<td align="char" valign="top" char="[">1.29 [0.88&#x2013;1.89]</td>
<td align="char" valign="top" char=".">0.1990</td>
<td align="char" valign="top" char="[">&#x2013;</td>
<td align="char" valign="top" char=".">&#x2013;</td>
</tr>
<tr>
<td align="left" valign="top">Prestroke disability (mRS 0 versus mRS 1&#x2013;6)</td>
<td align="char" valign="top" char="[">0.23 [0.15&#x2013;0.36]</td>
<td align="char" valign="top" char="."><bold>&#x003C;0.0001</bold></td>
<td align="char" valign="top" char="[">3.62 [2.27&#x2013;5.76]</td>
<td align="char" valign="top" char=".">&#x003C;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">NIHSS at admission (&#x003C;5 versus&#x2009;&#x2265;&#x2009;5)</td>
<td align="char" valign="top" char="[">0.55 [0.39&#x2013;0.78]</td>
<td align="char" valign="top" char="."><bold>0.001</bold></td>
<td align="char" valign="top" char="[">1.75 [1.19&#x2013;2.58]</td>
<td align="char" valign="top" char=".">0.005</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale. In bold are variables with a value of <italic>p</italic>&#x2009;&#x2264;&#x2009;0.1 that were included in the multivariable regression models.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec sec-type="discussion" id="sec12">
<label>4</label>
<title>Discussion</title>
<p>This study showed that female sex is an independent predictor of a 90-day worse functional outcome in patients with LS treated with IVT. This result, not specifically addressed before, is novel and in line with a previous specific sex-oriented observation performed by our group on IVT efficacy in AIS patients across all stroke subtypes (<xref ref-type="bibr" rid="ref14">14</xref>).</p>
<p>The reasons behind sex differences in IVT functional outcomes in LS patients are probably multifactorial. First, female patients in our study cohort were older than male patients. Although previous studies have shown that the worse functional outcome after IVT in female patients compared to male patients is not age-dependent (<xref ref-type="bibr" rid="ref15">15</xref>), additional unmeasured sex- and age-related differences in vascular mechanisms might be involved (such as platelet reactivity or an increase in chronic low-grade systemic inflammation, which has been described to be higher in elderly female patients) (<xref ref-type="bibr" rid="ref16">16</xref>). Second, the same vascular mechanisms could influence the safety of IVT in LS patients differently between female and male patients. Notably, in our study population, sICH, a feared side effect in patients with small vessel disease, was a rare event. Third, some environmental and social conditions, such as the pre- and post-hospital living situation, might have influenced the worse functional outcome of IVT among female patients with LS. However, despite correcting for the pre-stroke Rankin scale score and choosing a shift analysis as the primary outcome measure, the SSR does not collect detailed information about patient living and social conditions. A fourth factor potentially influencing sex differences in the functional outcome of IVT among LS patients may be related to disparities between male and female patients in acute stroke management, as reported in previous studies (<xref ref-type="bibr" rid="ref17">17</xref>). However, we found no differences in the timing of treatment between the two sexes. Finally, the different locations of ischemic lesions between female and male patients could have contributed to the worse functional outcome observed in female patients (<xref ref-type="bibr" rid="ref18">18</xref>). Nevertheless, based on the variables collected within the SSR, we cannot know the specific volumetric measurements of ischemic lesions as well as their location and other neuroimaging details.</p>
<p>Although the national coverage of the SSR may limit the generalizability of the results, the present study evaluates a numerically significant cohort of LS patients with IVT, leveraging the need for future studies aimed at defining the sex-specific mechanisms underlying a worse functional outcome of IVT in female patients with LS.</p>
</sec>
<sec sec-type="data-availability" id="sec13">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, on request.</p>
</sec>
<sec sec-type="ethics-statement" id="sec14">
<title>Ethics statement</title>
<p>The study was approved by Comitato Etico Canton Ticino (CE Req-2020-01042). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec15">
<title>Author contributions</title>
<p>PW: Data curation, Validation, Visualization, Writing &#x2013; original draft. RN: Data curation, Formal analysis, Investigation, Software, Validation, Visualization, Writing &#x2013; original draft. AP: Data curation, Formal analysis, Investigation, Methodology, Software, Writing &#x2013; review &#x0026; editing. GB: Resources, Writing &#x2013; review &#x0026; editing. DS: Resources, Writing &#x2013; review &#x0026; editing. PM: Resources, Writing &#x2013; review &#x0026; editing. KN: Resources, Writing &#x2013; review &#x0026; editing. LB: Resources, Writing &#x2013; review &#x0026; editing. GK: Resources, Writing &#x2013; review &#x0026; editing. JN: Resources, Writing &#x2013; review &#x0026; editing. TN: Resources, Writing &#x2013; review &#x0026; editing. AL: Resources, Writing &#x2013; review &#x0026; editing. SW: Resources, Writing &#x2013; review &#x0026; editing. LS: Resources, Writing &#x2013; review &#x0026; editing. FM: Resources, Writing &#x2013; review &#x0026; editing. BR: Resources, Writing &#x2013; review &#x0026; editing. NP: Resources, Writing &#x2013; review &#x0026; editing. SR: Resources, Writing &#x2013; review &#x0026; editing. MM: Resources, Writing &#x2013; review &#x0026; editing. EC: Resources, Writing &#x2013; review &#x0026; editing. UF: Resources, Writing &#x2013; review &#x0026; editing. GM: Resources, Writing &#x2013; review &#x0026; editing. CC: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Visualization, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec16">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="sec17">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec18">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fneur.2024.1341423/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fneur.2024.1341423/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname> <given-names>S</given-names></name> <name><surname>Marini</surname> <given-names>C</given-names></name> <name><surname>Totaro</surname> <given-names>R</given-names></name> <name><surname>Russo</surname> <given-names>T</given-names></name> <name><surname>Cerone</surname> <given-names>D</given-names></name> <name><surname>Carolei</surname> <given-names>A</given-names></name></person-group>. <article-title>A population-based study of the incidence and prognosis of lacunar stroke</article-title>. <source>Neurology</source>. (<year>2006</year>) <volume>66</volume>:<fpage>1335</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000210457.89798.0e</pub-id>, PMID: <pub-id pub-id-type="pmid">16682663</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname> <given-names>JM</given-names></name> <name><surname>Smith</surname> <given-names>C</given-names></name> <name><surname>Dichgans</surname> <given-names>M</given-names></name></person-group>. <article-title>Small vessel disease: mechanisms and clinical implications</article-title>. <source>Lancet Neurol</source>. (<year>2019</year>) <volume>18</volume>:<fpage>684</fpage>&#x2013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(19)30079-1</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Markus</surname> <given-names>HS</given-names></name> <name><surname>de Leeuw</surname> <given-names>FE</given-names></name></person-group>. <article-title>Cerebral small vessel disease: recent advances and future directions</article-title>. <source>Int J Stroke</source>. (<year>2023</year>) <volume>18</volume>:<fpage>4</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1177/17474930221144911</pub-id>, PMID: <pub-id pub-id-type="pmid">36575578</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pantoni</surname> <given-names>L</given-names></name></person-group>. <article-title>Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges</article-title>. <source>Lancet Neurol</source>. (<year>2010</year>) <volume>9</volume>:<fpage>689</fpage>&#x2013;<lpage>701</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(10)70104-6</pub-id>, PMID: <pub-id pub-id-type="pmid">20610345</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pantoni</surname> <given-names>L</given-names></name> <name><surname>Fierini</surname> <given-names>F</given-names></name> <name><surname>Poggesi</surname> <given-names>A</given-names></name></person-group>. <article-title>Thrombolysis in acute stroke patients with cerebral small vessel disease</article-title>. <source>Cerebrovasc Dis</source>. (<year>2014</year>) <volume>37</volume>:<fpage>5</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000356796</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caplan</surname> <given-names>LR</given-names></name> <name><surname>Mohr</surname> <given-names>JP</given-names></name> <name><surname>Kistler</surname> <given-names>JP</given-names></name> <name><surname>Koroshetz</surname> <given-names>W</given-names></name></person-group>. <article-title>Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis--not a panacea for ischemic stroke</article-title>. <source>N Engl J Med</source>. (<year>1997</year>) <volume>337</volume>:<fpage>1309</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199710303371812</pub-id>, PMID: <pub-id pub-id-type="pmid">9345084</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><collab id="coll1">National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group</collab></person-group>. <article-title>Tissue plasminogen activator for acute ischemic stroke</article-title>. <source>N Engl J Med</source>. (<year>1995</year>) <volume>333</volume>:<fpage>1581</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199512143332401</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matusevicius</surname> <given-names>M</given-names></name> <name><surname>Paciaroni</surname> <given-names>M</given-names></name> <name><surname>Caso</surname> <given-names>V</given-names></name> <name><surname>Bottai</surname> <given-names>M</given-names></name> <name><surname>Khurana</surname> <given-names>D</given-names></name> <name><surname>de Bastos</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Outcome after intravenous thrombolysis in patients with acute lacunar stroke: an observational study based on SITS international registry and a meta-analysis</article-title>. <source>Int J Stroke</source>. (<year>2019</year>) <volume>14</volume>:<fpage>878</fpage>&#x2013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1747493019840947</pub-id>, PMID: <pub-id pub-id-type="pmid">30935349</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barow</surname> <given-names>E</given-names></name> <name><surname>Boutitie</surname> <given-names>F</given-names></name> <name><surname>Cheng</surname> <given-names>B</given-names></name> <name><surname>Cho</surname> <given-names>TH</given-names></name> <name><surname>Ebinger</surname> <given-names>M</given-names></name> <name><surname>Endres</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>WAKE-UP investigators. Functional outcome of intravenous thrombolysis in patients with lacunar infarcts in the WAKE-UP trial</article-title>. <source>JAMA Neurol</source>. (<year>2019</year>) <volume>76</volume>:<fpage>641</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.0351</pub-id>, PMID: <pub-id pub-id-type="pmid">30907934</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arboix</surname> <given-names>A</given-names></name> <name><surname>Massons</surname> <given-names>J</given-names></name> <name><surname>Garc&#x00ED;a-Eroles</surname> <given-names>L</given-names></name> <name><surname>Targa</surname> <given-names>C</given-names></name> <name><surname>Comes</surname> <given-names>E</given-names></name> <name><surname>Parra</surname> <given-names>O</given-names></name> <etal/></person-group>. <article-title>Nineteen-year trends in risk factors, clinical characteristics and prognosis in lacunar infarcts</article-title>. <source>Neuroepidemiology</source>. (<year>2010</year>) <volume>35</volume>:<fpage>231</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000319460</pub-id>, PMID: <pub-id pub-id-type="pmid">20861654</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jim&#x00E9;nez-S&#x00E1;nchez</surname> <given-names>L</given-names></name> <name><surname>Hamilton</surname> <given-names>OKL</given-names></name> <name><surname>Clancy</surname> <given-names>U</given-names></name> <name><surname>Backhouse</surname> <given-names>EV</given-names></name> <name><surname>Stewart</surname> <given-names>CR</given-names></name> <name><surname>Stringer</surname> <given-names>MS</given-names></name> <etal/></person-group>. <article-title>Sex differences in cerebral small vessel disease: a systematic review and Meta-analysis</article-title>. <source>Front Neurol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>756887</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2021.756887</pub-id>, PMID: <pub-id pub-id-type="pmid">34777227</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arboix</surname> <given-names>A</given-names></name> <name><surname>Cartany&#x00E0;</surname> <given-names>A</given-names></name> <name><surname>Lowak</surname> <given-names>M</given-names></name> <name><surname>Garc&#x00ED;a-Eroles</surname> <given-names>L</given-names></name> <name><surname>Parra</surname> <given-names>O</given-names></name> <name><surname>Oliveres</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Gender differences and woman-specific trends in acute stroke: results from a hospital-based registry (1986-2009)</article-title>. <source>Clin Neurol Neurosurg</source>. (<year>2014</year>) <volume>127</volume>:<fpage>19</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clineuro.2014.09.024</pub-id>, PMID: <pub-id pub-id-type="pmid">25459238</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>HP</given-names> <suffix>Jr</suffix></name> <name><surname>Bendixen</surname> <given-names>BH</given-names></name> <name><surname>Kappelle</surname> <given-names>LJ</given-names></name> <name><surname>Biller</surname> <given-names>J</given-names></name> <name><surname>Love</surname> <given-names>BB</given-names></name> <name><surname>Gordon</surname> <given-names>DL</given-names></name> <etal/></person-group>. <article-title>Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment</article-title>. <source>Stroke</source>. (<year>1993</year>) <volume>24</volume>:<fpage>35</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.str.24.1.35</pub-id>, PMID: <pub-id pub-id-type="pmid">7678184</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noseda</surname> <given-names>R</given-names></name> <name><surname>Rea</surname> <given-names>F</given-names></name> <name><surname>Pagnamenta</surname> <given-names>A</given-names></name> <name><surname>Agazzi</surname> <given-names>P</given-names></name> <name><surname>Bianco</surname> <given-names>G</given-names></name> <name><surname>Sihabdeen</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Sex differences in outcomes of intravenous thrombolysis in acute ischemic stroke patients with preadmission use of Antiplatelets</article-title>. <source>CNS Drugs</source>. (<year>2023</year>) <volume>37</volume>:<fpage>351</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40263-023-00997-7</pub-id>, PMID: <pub-id pub-id-type="pmid">36976463</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spaander</surname> <given-names>FH</given-names></name> <name><surname>Zinkstok</surname> <given-names>SM</given-names></name> <name><surname>Baharoglu</surname> <given-names>IM</given-names></name> <name><surname>Gensicke</surname> <given-names>H</given-names></name> <name><surname>Polymeris</surname> <given-names>A</given-names></name> <name><surname>Traenka</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Sex differences and functional outcome after intravenous thrombolysis</article-title>. <source>Stroke</source>. (<year>2017</year>) <volume>48</volume>:<fpage>699</fpage>&#x2013;<lpage>703</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.116.014739</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabetta</surname> <given-names>A</given-names></name> <name><surname>Lombardi</surname> <given-names>L</given-names></name> <name><surname>Stefanini</surname> <given-names>L</given-names></name></person-group>. <article-title>Sex differences at the platelet-vascular interface</article-title>. <source>Intern Emerg Med</source>. (<year>2022</year>) <volume>17</volume>:<fpage>1267</fpage>&#x2013;<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11739-022-02994-y</pub-id>, PMID: <pub-id pub-id-type="pmid">35576047</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gargano</surname> <given-names>JW</given-names></name> <name><surname>Wehner</surname> <given-names>S</given-names></name> <name><surname>Reeves</surname> <given-names>MJ</given-names></name></person-group>. <article-title>Do presenting symptoms explain sex differences in emergency department delays among patients with acute stroke?</article-title> <source>Stroke</source>. (<year>2009</year>) <volume>40</volume>:<fpage>1114</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.108.543116</pub-id>, PMID: <pub-id pub-id-type="pmid">19211483</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname> <given-names>WS</given-names></name> <name><surname>Chung</surname> <given-names>J</given-names></name> <name><surname>Schellingerhout</surname> <given-names>D</given-names></name> <name><surname>Jeong</surname> <given-names>SW</given-names></name> <name><surname>Kim</surname> <given-names>HR</given-names></name> <name><surname>Park</surname> <given-names>JE</given-names></name> <etal/></person-group>. <article-title>Biological mechanism of sex difference in stroke manifestation and outcomes</article-title>. <source>Neurology</source>. (<year>2023</year>) <volume>100</volume>:<fpage>e2490</fpage>&#x2013;<lpage>503</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000207346</pub-id>, PMID: <pub-id pub-id-type="pmid">37094993</pub-id></citation></ref>
</ref-list>
</back>
</article>
